Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
Status:
Terminated
Trial end date:
2019-02-11
Target enrollment:
Participant gender:
Summary
The purpose of the study is to observe the effect of sorafenib combined with aspirin in
preventing the recurrence in high-risk patients with hepatocellular carcinoma.